• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

了解抗癌卤化抑制剂和酪蛋白激酶 2 (CK2)的各种官能团(X=Cl、F、CF、CH、NH、OH、H)的影响。

Understanding the impact of anticancer halogenated inhibitors and various functional groups (X = Cl, F, CF, CH, NH, OH, H) of casein kinase 2 (CK2).

机构信息

Department of Physics, Manonmaniam Sundaranar University, Tirunelveli, India.

Department of Animal Nutrition, Veterinary College and Research Institute, Tamil Nadu Veterinary and Animal Sciences University, Tirunelveli, India.

出版信息

J Biomol Struct Dyn. 2022 Jul;40(11):5036-5052. doi: 10.1080/07391102.2020.1866075. Epub 2020 Dec 29.

DOI:10.1080/07391102.2020.1866075
PMID:33375908
Abstract

Main focus of study is to understand potency of halogen (X = Br) atom that exists in tetrabromobenzotriazole (TBB) derivatives of crystal CK2 ligand along with hinge region amino acids (VAL45, PHE113, GLU114, VAL116, ASN118) through interaction energy analysis. In turn to attain profound insight on nature of stabilization of core CK2 ligands: 1ZOE-L1, 1ZOG-L2, 1ZOH-L3, 2OXX-L4, 2OXY-L5, 3KXG-L6, 3KXH-L7 -L7 and 3KXM-L8, having four bromine atoms, we attempted to mutate all bromine (X = Br) atoms by various functional groups (X = Cl, F, CF, CH, NH, OH, H) and binding strength along with amino acids was calculated. Most stable ligands exist in mutated NH functional groups: 1ZOG-L2, 1ZOH-L3, 2OXX-L4, 3KXM-L8 having interaction energy as -5.21, -14.87, -6.69 and -11.72 kcal/mol respectively, revealing strong binding strength. Second most stable mutated Cl functional group ligands also play a major role in 1ZOH-L3, 2OXX-L4 and 3KXM-L8 having interaction energy as -6.89, -5.37, and -10.48 kcal/mol respectively. Overall, this study will pave way for crystal growth and medicinal chemist to have cleared perceptive about structural properties of CK2 halogenated ligands with new insight on CK2 mutated functional group ligands. Further, it insists us to reuse existing CK2 crystal ligand with more preferable suggested binding contacts in course of new functional groups that lead to anticancer affinity.Communicated by Ramaswamy H. Sarma.

摘要

本研究的重点是通过相互作用能分析,了解晶体 CK2 配体中四溴苯并三唑(TBB)衍生物中卤素(X=Br)原子与铰链区氨基酸(VAL45、PHE113、GLU114、VAL116、ASN118)的结合能力。反过来,通过深入了解核心 CK2 配体的稳定性性质:1ZOE-L1、1ZOG-L2、1ZOH-L3、2OXX-L4、2OXY-L5、3KXG-L6、3KXH-L7、3KXM-L8,这些配体有四个溴原子,我们试图通过各种官能团(X=Cl、F、CF、CH、NH、OH、H)取代所有溴原子(X=Br),并计算与氨基酸的结合强度。最稳定的配体存在于取代的 NH 官能团中:1ZOG-L2、1ZOH-L3、2OXX-L4、3KXM-L8 的相互作用能分别为-5.21、-14.87、-6.69 和-11.72 kcal/mol,表明具有较强的结合强度。其次稳定的取代 Cl 官能团配体在 1ZOH-L3、2OXX-L4 和 3KXM-L8 中也起着重要作用,其相互作用能分别为-6.89、-5.37 和-10.48 kcal/mol。总的来说,这项研究为晶体生长和药物化学家提供了一个途径,使他们对 CK2 卤化配体的结构性质有了更清晰的认识,并对 CK2 突变官能团配体有了新的认识。此外,它还促使我们在新的官能团中重新使用现有的 CK2 晶体配体,并选择更理想的建议结合接触,从而提高抗癌亲和力。由 Ramaswamy H. Sarma 传达。

相似文献

1
Understanding the impact of anticancer halogenated inhibitors and various functional groups (X = Cl, F, CF, CH, NH, OH, H) of casein kinase 2 (CK2).了解抗癌卤化抑制剂和酪蛋白激酶 2 (CK2)的各种官能团(X=Cl、F、CF、CH、NH、OH、H)的影响。
J Biomol Struct Dyn. 2022 Jul;40(11):5036-5052. doi: 10.1080/07391102.2020.1866075. Epub 2020 Dec 29.
2
An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.铰链区对 CK2 配体抗癌结合亲和力影响的概述:量子化学分析。
J Biomol Struct Dyn. 2019 Sep;37(15):3859-3876. doi: 10.1080/07391102.2018.1533498. Epub 2018 Dec 5.
3
Rising trend on the halogen and non-halogen derivatives (Br, Cl, CF, F, CH and NH) in ruminal β-d-Xylopyranose - a quantum chemical perspective.瘤胃内β-D-木吡喃糖的卤族和非卤族衍生物(Br、Cl、CF、F、CH 和 NH)呈上升趋势——量子化学视角。
J Biomol Struct Dyn. 2022 Jan;40(1):449-467. doi: 10.1080/07391102.2020.1815577. Epub 2020 Sep 3.
4
Understanding the impact of halogen functional group (Br, Cl, F, OH) in amprenavir ligand of the HIV protease.了解卤族官能团(Br、Cl、F、OH)在 HIV 蛋白酶抑制剂阿巴卡韦配体中的影响。
J Biomol Struct Dyn. 2023;41(21):12157-12170. doi: 10.1080/07391102.2023.2166121. Epub 2023 Jan 16.
5
Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.考察源自四溴苯并咪唑的蛋白激酶CK2抑制剂的构效关系。
Chem Biol. 2005 Nov;12(11):1211-9. doi: 10.1016/j.chembiol.2005.08.015.
6
From Short-Bite Ligand Assembled Ribbons to Nanosized Networks in Cu(I) Coordination Polymers Built Upon Bis(benzylthio)alkanes (BzS(CH)SBz; = 1-9).从短咬合配体组装的带状结构到基于双(苄硫基)烷烃(BzS(CH)SBz;n = 1-9)构建的铜(I)配位聚合物中的纳米尺寸网络结构。
Inorg Chem. 2020 Mar 16;59(6):3686-3708. doi: 10.1021/acs.inorgchem.9b03275. Epub 2020 Mar 5.
7
Understanding the potency of malarial ligand (D44) in plasmodium FKBP35 and modelled halogen atom (Br, Cl, F) functional groups.了解疟原虫FKBP35中疟疾配体(D44)的效力以及模拟的卤素原子(溴、氯、氟)官能团。
J Mol Graph Model. 2020 Jun;97:107553. doi: 10.1016/j.jmgm.2020.107553. Epub 2020 Jan 31.
8
Syntheses of 8-quinolinolatocobalt(III) complexes containing cyclen based auxiliary ligands as models for hypoxia-activated prodrugs.合成含环戊二烯基辅助配体的 8-喹啉酸钴(III)配合物作为缺氧激活前药的模型。
Dalton Trans. 2010 Dec 28;39(48):11535-50. doi: 10.1039/c0dt01142h. Epub 2010 Nov 22.
9
A competition between hydrophobic and electrostatic interactions in protein-ligand systems. Binding of heterogeneously halogenated benzotriazoles by the catalytic subunit of human protein kinase CK2.蛋白质-配体系统中疏水相互作用与静电相互作用之间的竞争。人蛋白激酶CK2催化亚基对异质卤代苯并三唑的结合
IUBMB Life. 2020 Jun;72(6):1211-1219. doi: 10.1002/iub.2271. Epub 2020 Mar 12.
10
Alternative binding modes of an inhibitor to two different kinases.一种抑制剂与两种不同激酶的交替结合模式。
Eur J Biochem. 2003 Aug;270(15):3174-81. doi: 10.1046/j.1432-1033.2003.03697.x.

引用本文的文献

1
Chemical Probes Review: Choosing the Right Path Towards Pharmacological Targets in Drug Discovery, Challenges and Future Perspectives.化学探针综述:在药物发现中选择药理学靶点的正确途径、挑战与未来展望。
Comb Chem High Throughput Screen. 2024;27(17):2544-2564. doi: 10.2174/0113862073283304231118155730.